Pixyl Nets FDA Clearance for AI-Powered Brain MR Software

Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro AI software for brain MR analysis that recently demonstrated enhanced detection rates up to 28% according to Dehaene, et al. (ESNR 2023). Pixyl.Neuro automatically analyzes brain MR images to support rapid detection, early diagnosis and objective monitoring of neurological disorders, leveraging generative AI technology to ensure robust performance in real-world practice.

“AI-driven MRI analysis opens the possibility of accessing previously unavailable clinically-relevant information to reinforce radiology workflows, especially in the context of neurological disorders.” explains Prof Lotfi Hacein-Bey, Chief of Division of Neuroradiology at UC Davis. “With disease modifying treatments for MS and now Alzheimer disease, it is more important than ever to highlight activity and monitor disease evolution.”

Pixyl.Neuro was designed to improve detection of neurological disease activity, accelerate MRI reading time, and provide peace-of-mind for the 83% of MS MRI exams that are stable (Cohen, et al., BMC Neurology, 2016). Brain region volumes are quantified and compared to normative data to identify abnormal atrophy earlier and help support differential diagnosis. The solution uses minimal MRI protocols and provides results in a matter of minutes.

According to Prof Hacein-Bey, “Pixyl's FDA approval holds great promise for supporting the management of neurodegenerative and neuroinflammatory disorders. We chose Pixyl to answer our routine practice needs based on their track-record of delivering high-quality brain MRI solutions. I am delighted to partner with Pixyl and I look forward to the benefits it will bring to our radiology workflow and patient care.”

Pixyl's adherence to the latest FDA AI guidelines in obtaining approval underscores their commitment to developing high-quality medical imaging AI solutions. Additionally, Pixyl.Neuro has received the CE-mark class IIa certification in the European Union under the new Medical Device Regulations.

Precision medicine heralds a new era in patient care. One where medical professionals using the latest AI solutions can rapidly access the information needed to diagnose and manage diseases earlier. As noted by Senan Doyle, CEO at Pixyl, “It is incredibly rewarding to receive feedback from Pixyl.Neuro users who attest to this valuable support. We are delighted to work with US radiologists and imaging centers to reinforce radiology workflows and patient care.”

© Anderson Publishing, Ltd. 2024 All rights reserved. Reproduction in whole or part without express written permission Is strictly prohibited.